Medipol University — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
26G NeedleThis randomized split-face study aims to compare the effects of 26G and 30G needles used for masseter trigger point injections with lidocaine in patients with myofascial pain syndrome. Both needle sizes are routinely used in clinical practice. Pain reduction from baseline to day 14 will be compared between the two sides of the face. Secondary outcomes include pain reduction at day 7, procedural pain, injection-site tenderness at 48 hours, bruising, and patient preference. The split-face design allows both needle sizes to be evaluated in the same patient, minimizing individual differences.	Myopathies	Non applicable	Traitement symptomatique	Turkey (Türkiye)	À vérifier
30 Gauge NeedleThis randomized split-face study aims to compare the effects of 26G and 30G needles used for masseter trigger point injections with lidocaine in patients with myofascial pain syndrome. Both needle sizes are routinely used in clinical practice. Pain reduction from baseline to day 14 will be compared between the two sides of the face. Secondary outcomes include pain reduction at day 7, procedural pain, injection-site tenderness at 48 hours, bruising, and patient preference. The split-face design allows both needle sizes to be evaluated in the same patient, minimizing individual differences.	Myopathies	Non applicable	Traitement symptomatique	Turkey (Türkiye)	À vérifier
26G NeedleThis randomized split-face study aims to compare the effects of 26G and 30G needles used for masseter trigger point injections with lidocaine in patients with myofascial pain syndrome. Both needle sizes are routinely used in clinical practice. Pain reduction from baseline to day 14 will be compared between the two sides of the face. Secondary outcomes include pain reduction at day 7, procedural pain, injection-site tenderness at 48 hours, bruising, and patient preference. The split-face design allows both needle sizes to be evaluated in the same patient, minimizing individual differences.	Myopathies	Non applicable	Traitement symptomatique	Turkey (Türkiye)	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
26G Needle	Myopathies	Non applicable	NCT07926113	MASS-NEEDLE — Comparison of 26G and 30G Needles for Masseter Trigger Point Injections in Patients With Myofascial Pain Syndrome	NOT_YET_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.